Annals of Oncology Advance Access originally published online on December 12, 2006
Annals of Oncology 2007 18(3):510-517; doi:10.1093/annonc/mdl459
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
gastrointestinal tumors |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
1 Medical Oncology, S. Orsola-Malpighi Hospital, Bologna
2 Medical Oncology, Falck Division, Niguarda Cà Granda Hospital, Milan
3 Medical Oncology, University of Marche, Umberto I Hospital, Ancona
4 Pathology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy
* Correspondence to: Dr C. Pinto, Medical Oncology Unit, S. Orsola-Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy; E-mail: cpinto{at}aosp.bo.it
Background: The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Patients and methods: Untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received cetuximab at an initial dose of 400 mg/m2 intravenously (i.v.) followed by weekly doses of 250 mg/m2, CPT 11 180 mg/m2 i.v. on day 1, LFA 100 mg/m2 i.v. followed by 5-FU 400 mg/m2 i.v. bolus, and 600 mg/m2 i.v. 22-h continuous infusion on days 1 and 2 (FOLFIRI) every 2 weeks, for a maximum of 24 weeks, then cetuximab alone was allowed in patients with a complete response, partial response, or stable disease. Antitumor activity was assessed by computed tomography (CT) and positron emission tomography (PET) at baseline and after 6 weeks, and further by CT alone or CT and PET every 6 weeks.
Results: Thirty-eight patients were enrolled (median age 63.5 years, range 39–83; median Karnofsky performance status 90, range 70–100; stomach 89.5% and GEJ 10.5%; locally advanced disease 13.2% and metastatic disease 86.8%). All 38 patients were assessed for safety and survival, and 34 patients were assessed for overall response rates (ORR). The ORR was 44.1% [95% confidence interval (CI) 27.5% to 60.9%]. The median time-to-progression was 8 months (95% CI 7–9). At the median follow-up time of 11 months, 55.3% of patients were alive, with a median expected survival time of 16 months (95% CI 9–23). Grade 3–4 toxicity included neutropenia (42.1%), acne-like rash (21.1%), diarrhea (7.9%), asthenia (5.3%), stomatitis (5.3%), and hypertransaminasemia (5.3%). There was one (2.6%) treatment-related death.
Conclusions: The combination of cetuximab and FOLFIRI is active in gastric and GEJ adenocarcinoma. The higher toxicity appears to be limited to neutropenia.
Key words: advanced gastric cancer, Cetuximab, FOLFIRI regimen
Received for publication August 28, 2006. Revision received October 30, 2006. Accepted for publication November 2, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D.G. Power and D.H. Ilson Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 145 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer Ann. Onc., July 1, 2009; 20(7): 1242 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Goekkurt, S.-E. Al-Batran, U. Mogck, C. Pauligk, J. T. Hartmann, M. Kramer, E. Jaeger, G. Ehninger, and J. Stoehlmacher Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Ann. Onc., March 1, 2009; 20(3): 481 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dank, J. Zaluski, C. Barone, V. Valvere, S. Yalcin, C. Peschel, M. Wenczl, E. Goker, L. Cisar, K. Wang, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann. Onc., August 1, 2008; 19(8): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pozzo and C. Barone Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents? Oncologist, July 1, 2008; 13(7): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N. T. Okita, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, and T. Shimoda Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3022 - 3029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy Oncologist, October 1, 2007; 12(10): 1165 - 1177. [Abstract] [Full Text] [PDF]
|
|